CompletedPhase 2NCT04412057

Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury

Studying Adult acute respiratory distress syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Principal Investigator
Scott White, MD, M.D
Aevi Genomic Medicine, LLC, a Cerecor company
Intervention
CERC-002(drug)
Enrollment
88 enrolled
Eligibility
18 years · All sexes
Timeline
20202021

Study locations (11)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04412057 on ClinicalTrials.gov

Other trials for Adult acute respiratory distress syndrome

Additional recruiting or active studies for the same condition.

See all trials for Adult acute respiratory distress syndrome

← Back to all trials